While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel supplying blood to the brain is obstructed), bleeding or thromboembolism (a condition that happens when a blood clot forms elsewhere in the body and travels through the blood stream to plug another vessel), limited data are available on the number of NVAF patients and the reasons why NVAF patients in Italy stop or change their treatment with blood thinners to prevent stroke or thromboembolism.
By following the NVAF patients in routine clinical practice in Italy who are treated with rivaroxaban to prevent stroke or systemic embolism researchers want to find out how many NVAF patients and for what reasons NVAF patients stopped or changed rivaroxaban treatment. Study data will be collected through patients' routine visits at their treating doctor over a period of 24 months for each patient.
Source : Importé depuis le centre
RECRUTEMENT
Profil des participants
Limites d'âge
minimum : 18 ans
Sexe(s) des participants
ALL
Source : Importé depuis le centre
Condition médicale (spécialité visée)
Domaine de recherche
Donnée non disponible
Critères de sélection
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
NVAF patients
Start treatment with rivaroxaban at the discretion of physician.
Donnée non disponible
Inconnu
NVAF patients
État du recrutement
unknown
Start treatment with rivaroxaban at the discretion of physician.
Données à jour depuis :
17 octobre 2024
SITES ET CONTACTS
Centre principal
many locations
MULTIPLE LOCATIONS, WEST VIRGINIA, ARGENTINA
Recrutement local
—
FERMÉ
Dernière modification :
17 octobre 2024
Données à jour depuis :
19 oct.
Origine des données :
clinicaltrials.gov
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles
Identifiant
20999
Titre
Study aims to collect information in routine clinical practice in italy about the number of patients suffering from irregularly heart beats which are not caused by a heart valve problem (non-valvular atrial fibrillation, nvaf) who stopped or changed rivaroxaban treatment
* Age \>= 18
* Patient with a diagnosis of NVAF
* New user to rivaroxaban, naïve or non naïve to treatment with oral anticoagulant
* Patient for whom the decision to initiate treatment with rivaroxaban was made as per physician's routine treatment practice for prevention of stroke and non-central nervous system (CNS) systemic embolism
* Signed an informed consent
Exclusion Criteria:
* Patient with heart valve replacement
* Patient is participating in an investigational program with interventions outside of routine clinical practice
Source : Importé depuis le centre
Cohortes
Thérapie ou Intervention proposée
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
NVAF patients
Start treatment with rivaroxaban at the discretion of physician.
Donnée non disponible
Inconnu
NVAF patients
État du recrutement
unknown
Start treatment with rivaroxaban at the discretion of physician.
Données à jour depuis :
17 octobre 2024
Description de l'étude
Description de l'étude
Résumé de l'étude
While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel supplying blood to the brain is obstructed), bleeding or thromboembolism (a condition that happens when a blood clot forms elsewhere in the body and travels through the blood stream to plug another vessel), limited data are available on the number of NVAF patients and the reasons why NVAF patients in Italy stop or change their treatment with blood thinners to prevent stroke or thromboembolism.
By following the NVAF patients in routine clinical practice in Italy who are treated with rivaroxaban to prevent stroke or systemic embolism researchers want to find out how many NVAF patients and for what reasons NVAF patients stopped or changed rivaroxaban treatment. Study data will be collected through patients' routine visits at their treating doctor over a period of 24 months for each patient.
Source : Importé depuis le centre
Centres participants
Sites
Centres participants
1
centres
MANY LOCATIONS
Multiple locations
WEST VIRGINIA, ARGENTINA
Recrutement local
État du recrutement:
FERMÉ
Source d'information
Dernière modification :
17 octobre 2024
Données à jour depuis :
19 oct.
Origine des données :
clinicaltrials.gov